A Massachusetts biotechnology company is laying off nearly 500 employees, more than a third of its total workforce, as it faces pushback from the U.S. Food and Drug Administration on one of its ...

An estimated 53 drugs would not enter the market in the next 30 years if the NIH is hit with a permanent 10% budget cut and the FDA experiences a nine-month drug review delay due to staffing cuts, the ...

The U.S. Congressional Budget Office (CBO) cautioned that President Trumps proposed 2026 federal budgetfeaturing deep cuts to ...

The Trump administration’s proposed cuts to medical research and health agencies will curtail the development of promising ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

The mass firing of State Department employees could significantly impact the Trump administration’s ability to address the ...

Other agencies are moving forward with RIFs and terminations, but official tells federal court some plans have changed.

Loss of support staff has slowed critical investigations of drug manufacturers. Little relief has materialized.

Federal agency leaders still face obstacles to implementing widespread layoffs, and some are even reversing course after the ...

Beyond staff cuts, the departures of some longtime investigators in recent months have left less experienced people tasked ...

Cuts at the FDA are slowing inspections of overseas drug manufacturers, prompting concerns from former and current employees that medication safety could be at risk, ProPublica reported July 7. Dozens ...